Nexalin Technology (NXL) Non Operating Investment Income (2023 - 2026)
Nexalin Technology's (NXL) quarterly Non Operating Investment Income came in at $88.0 in Q1 2026, down 89.4% year-on-year from $830.0 in Q1 2025, and down 91.52% quarter-over-quarter from $1038.0 in Q4 2025.
Nexalin Technology (NXL) Non Operating Investment Income (2023 - 2026) Analysis & Trends
Nexalin Technology's Non Operating Investment Income history runs 4 years deep, the most recent figure standing at $88.0 for Q1 2026.
- On a quarterly basis, Non Operating Investment Income fell 89.4% year-over-year to $88.0 in Q1 2026; TTM through Mar 2026 was $178.0, a 68.33% decrease from a year earlier, with the FY2025 full-year figure at $919.0, up 950.93% from the prior year.
- Non Operating Investment Income retreated to $88.0 in Q1 2026 per NXL's latest filing, from $1038.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $41069.0 in Q1 2023 and bottomed at -$32289.0 in Q3 2023.
- The 4-year median for Non Operating Investment Income is $88.0 (2026), against an average of $38.08.
- Biggest YoY gain for Non Operating Investment Income was 652.13% in 2025; the steepest drop was 349.54% in 2025.
- Year by year, Non Operating Investment Income stood at -$1205.0 in 2023, then soared by 84.4% to -$188.0 in 2024, then jumped by 652.13% to $1038.0 in 2025, then sank by 91.52% to $88.0 in 2026.
- Per Business Quant, the three latest NXL Non Operating Investment Income figures stand at $88.0 (Q1 2026), $1038.0 (Q4 2025), and -$1461.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | Nexalin Technology | 9.07 Mn | 6.36 Mn | 13,133.00 | 88.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.00 |
| Mar 31, 2026 | 88.00 |
| Dec 31, 2025 | 1,038.00 |
| Dec 31, 2025 | 1,038.00 |
| Sep 30, 2025 | -1,461.00 |
| Sep 30, 2025 | -1,461.00 |
| Jun 30, 2025 | 513.00 |
| Jun 30, 2025 | 513.00 |
| Mar 31, 2025 | 830.00 |
| Mar 31, 2025 | 830.00 |
| Dec 31, 2024 | -188.00 |
| Dec 31, 2024 | -188.00 |
| Sep 30, 2024 | -325.00 |
| Sep 30, 2024 | -325.00 |
| Jun 30, 2024 | 245.00 |
| Jun 30, 2024 | 245.00 |
| Mar 31, 2024 | 160.00 |
| Mar 31, 2024 | 160.00 |
| Dec 31, 2023 | -1,205.00 |
| Dec 31, 2023 | -1,205.00 |